Allogene Therapeutics (ALLO) Receivables - Accured (2018 - 2019)
Allogene Therapeutics' (ALLO) quarterly Receivables - Accured came in at $2.3 million in Q3 2019, down 28.86% quarter-over-quarter from $3.3 million in Q2 2019.
Allogene Therapeutics (ALLO) Receivables - Accured (2018 - 2019) Analysis & Trends
Allogene Therapeutics has disclosed Receivables - Accured across 2 years of filings, most recently posting $2.3 million for Q3 2019.
- Receivables - Accured for Q3 2019 came in at $2.3 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2019 was $2.3 million (changed N/A YoY), and the FY2018 annual result was $3.1 million, changed N/A from the prior year.
- Receivables - Accured came in at $2.3 million for Q3 2019 at Allogene Therapeutics, down from $3.3 million in the prior quarter.
- In the past five years, Receivables - Accured ranged from a high of $3.4 million in Q1 2019 to a low of $2.3 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Allogene Therapeutics | 482.98 Mn | 482.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 2.34 Mn |
| Sep 30, 2019 | 2.34 Mn |
| Jun 30, 2019 | 3.29 Mn |
| Jun 30, 2019 | 3.29 Mn |
| Mar 31, 2019 | 3.39 Mn |
| Mar 31, 2019 | 3.39 Mn |
| Dec 31, 2018 | 3.11 Mn |
| Dec 31, 2018 | 3.11 Mn |